Benchmark Reiterates Buy Rating on Unicycive Therapeutics
Benchmark keeps its buy rating for Unicycive Therapeutics, setting a $13 price target, a 169.78% upside from the current price.
Key Points
- Benchmark reiterated its buy rating for Unicycive Therapeutics, Inc. (UNCY) with a $13 price target on July 1, 2026.
- Benchmark's $13 price target implies 169.78% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.82 share price.
- Shares of Unicycive Therapeutics traded at $4.59 on Wednesday, with a market cap of approximately $128.5 million.
- Insiders, including CEO Shalabh Gupta, recently bought shares, and analysts maintain a strong buy consensus with a mean target price of $41.3.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Benchmark reiterated its buy rating for Unicycive Therapeutics, Inc. (NasdaqCM:UNCY) on July 1, 2026. The firm set a price target of $13 for the biotechnology company, reflecting continued confidence in its potential.
Benchmark vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Unicycive Therapeutics, Inc. Stock Down 8.5%
Shares of NasdaqCM:UNCY traded near $4.59 on Wednesday. Unicycive Therapeutics has a market cap of about $128.5 million and a forward P/E ratio of 0.86, indicating investor expectations for future earnings. The stock has a 52-week low of $3.71 and a high of $8.74, with a 50-day moving average of $7.56 and a 200-day moving average of $6.25. The company's beta is 1.726, suggesting it is more volatile than the market. Unicycive maintains a current ratio of 2.399 and a quick ratio of 2.061, with a debt-to-equity ratio of 2.162.
$UNCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several insiders at Unicycive Therapeutics, including CEO Shalabh Gupta, EVP Pharmaceuticals and BD Pramod Gupta, and CFO John Townsend, purchased shares. Each insider acquired shares at no disclosed price, indicating potential confidence in the company's prospects.
Analysts Set New Price Targets
On July 1, 2026, Benchmark reiterated its buy rating for Unicycive Therapeutics with a $13 price target. Noble Capital Markets also maintained its buy rating with a $50 target. HC Wainwright & Co. and B. Riley Securities both reiterated buy ratings on June 30, with targets of $15 and $22, respectively. The consensus among analysts is a strong buy, with a mean target price of $41.3 based on 10 analyst opinions.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Mountain View, California. It focuses on developing therapies for kidney diseases, including oxylanthanum carbonate for treating hyperphosphatemia in dialysis patients and UNI-494 for acute kidney injury. Led by CEO Dr. Pramod Gupta, the company was founded in 2016 and employs 21 people.
Bottom Line
Benchmark's reiterated buy rating and $13 price target highlight continued confidence in Unicycive Therapeutics' potential. The stock's recent trading levels and insider buying activity suggest investor interest. As a clinical-stage biotech, its future performance will depend on its progress in developing kidney disease therapies. Remember, analyst ratings are forward-looking opinions and not guarantees of future performance.
Get Unicycive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UNCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.